High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression

High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression

Show other versions (1)

Bibliographic Details
Main Authors:	Boultwood, J, Perry, J, Zaman, R, Fernandez-Santamaria, C, Littlewood, T, Kusec, R, Pellagatti, A, Wang, L, Clark, R, Wainscoat, J
Format:	Journal article
Published:	2010

Similar Items

High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression.
by: Boultwood, J, et al.
Published: (2010)

Frequent Mutation of the Polycomb-Associated Gene ASXL1 In Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
by: Fernandez-Mercado, M, et al.
Published: (2010)

Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia.
by: Boultwood, J, et al.
Published: (2010)

Frequent Mutation of the Polycomb-Associated Gene ASXL1 in the Myelodysplastic Syndromes and in Acute Myeloid Leukaemia
by: Boultwood, J, et al.
Published: (2009)

Analysis of telomere length in chronic myelogenous leukemia.
by: Boultwood, J, et al.
Published: (1997)

Analysis or telomere length in chronic myelogenous leukemia
by: Fidler, C, et al.
Published: (1998)

hTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia.
by: Campbell, L, et al.
Published: (2006)

Telomere length shortening is associated with disease evolution in chronic myelogenous leukemia.
by: Boultwood, J, et al.
Published: (1999)

AMPLIFICATION OF MITOCHONDRIAL-DNA IN ACUTE MYELOID-LEUKEMIA
by: Boultwood, J, et al.
Published: (1994)

Low expression of the putative tumour suppressor gene gravin in chronic myeloid leukaemia, myelodysplastic syndromes and acute myeloid leukaemia.
by: Boultwood, J, et al.
Published: (2004)

Heterogeneous leukemia stem cells in myeloid blast phase chronic myeloid leukemia
by: Kinstrie, R, et al.
Published: (2016)

Silencing of ASXL1 impairs the granulomonocytic lineage potential of human CD34+ progenitor cells
by: Davies, C, et al.
Published: (2013)

Silencing of ASXL1 impairs the granulomonocytic lineage potential of human CD34⁺ progenitor cells.
by: Davies, C, et al.
Published: (2013)

Bone marrow transplantation for patients with chronic myeloid leukemia.
by: Goldman, J, et al.
Published: (1986)

Mutations in PTPN11 are rare in adult myelodysplastic syndromes and acute myeloid leukemia.
by: Watkins, F, et al.
Published: (2004)

Recurrent SETBP1 mutations in atypical chronic myeloid leukemia
by: Piazza, R, et al.
Published: (2013)

Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.
by: Piazza, R, et al.
Published: (2013)

Amplification of mitochondrial DNA in acute myeloid leukaemia.
by: Boultwood, J, et al.
Published: (1996)

Recurrent ETNK1 mutations in atypical chronic myeloid leukemia.
by: Gambacorti-Passerini, C, et al.
Published: (2015)

Neutrophil gene expression in chronic myeloproliferative disorders.
by: Eagleton, H, et al.
Published: (2003)

BRCA2 gene deletion is rare in chronic lymphocytic leukemia.
by: Pilozzi, E, et al.
Published: (1998)

Glutathione S-transferase theta 1 (GSTT1) gene defect in myelodysplasia and acute myeloid leukaemia
by: Atoyebi, W, et al.
Published: (1997)

Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics
by: Fernandez-Mercado, M, et al.
Published: (2012)

Association between single nucleotide polymorphism-genotype and outcome of patients with chronic lymphocytic leukemia in a randomized chemotherapy trial.
by: Wade, R, et al.
Published: (2011)

Association between single nucleotide polymorphism-genotype and outcome of patients with chronic lymphocytic leukemia in a randomized chemotherapy trial.
by: Wade, R, et al.
Published: (2011)

Telomere length shortening in chronic myelogenous leukemia is associated with reduced time to accelerated phase.
by: Boultwood, J, et al.
Published: (2000)

HISTOCOMPATIBLE UNRELATED VOLUNTEER DONORS FOR BMT IN PATIENTS WITH CHRONIC MYELOID-LEUKEMIA
by: Mackinnon, S, et al.
Published: (1988)

Overcoming imatinib resistance conferred by the BIM deletion polymorphism in chronic myeloid leukemia with splice-switching antisense oligonucleotides
by: Liu, Jun, et al.
Published: (2018)

Imatinib mesylate in the treatment of chronic myeloid leukemia: a local experience
by: Bee, P.C., et al.
Published: (2006)

Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group.
by: Richards, S
Published: (1997)

Whole-exome sequencing in del(5q) myelodysplastic syndromes in transformation to acute myeloid leukemia
by: Pellagatti, A, et al.
Published: (2014)

Whole-exome sequencing in del(5q) myelodysplastic syndromes in transformation to acute myeloid leukemia.
by: Pellagatti, A, et al.
Published: (2014)

Treatment of chronic myeloid leukemia in rural Rwanda: promising early outcomes
by: Tapela, N, et al.
Published: (2016)

Identification of unbalanced genomic aberrations by array cgh in chronic myeloid leukemia patients with suboptimal response to imatinib treatment
by: Phan, C.L., et al.
Published: (2010)

De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways
by: Magistroni, V, et al.
Published: (2019)

Radiation-induced chromosome 2 rearrangement and initiation of murine acute myeloid leukemia.
by: Silver, A, et al.
Published: (1990)

Myeloid pre-leukemia and leukemia of Down syndrome
by: Cruz Hernandez, D, et al.
Published: (2020)

Bone marrow transplantation for chronic myeloid leukemia: the use of histocompatible unrelated volunteer donors.
by: Mackinnon, S, et al.
Published: (1990)

ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine
by: Rahmani, NE, et al.
Published: (2021)

MDMX acts as a pervasive preleukemic-to-acute myeloid leukemia transition mechanism
by: Ueda, K, et al.
Published: (2021)